Boston Scientific to Acquire American Medical Systems' Urology Portfolio

March 2, 2015—Boston Scientific Corporation announced that it has entered into a definitive agreement with Endo International plc to acquire the American Medical Systems’ (AMS) urology portfolio, which includes the men’s health and prostate health businesses, for $1.6 billion in cash and a potential additional $50 million milestone based on 2016 sales. The company expects to close the transaction in the third quarter of 2015, subject to customary closing conditions. The AMS men’s health and prostate health businesses will become part of Boston Scientific Urology and Women's Health. The AMS women’s health business is not included in the transaction.  

According to Boston Scientific, the acquisition encompasses the AMS product portfolio for treating men’s urologic conditions, including benign prostatic hyperplasia, male stress urinary incontinence, and erectile dysfunction. The AMS portfolio includes the GreenLight XPS and HPS laser therapy systems for treating benign prostatic hyperplasia, the AMS 800 urinary control system for treating stress urinary incontinence, and the AMS 700 inflatable penile prosthesis for treating erectile dysfunction.

The AMS men’s health and prostate health businesses are based in Minnetonka, Minnesota, and include approximately 800 employees worldwide. In 2014, the businesses generated sales of approximately $400 million, advised Boston Scientific.